Disposition of moracizine (ethmozine) in healthy subjects after oral administration of radiolabelled drug
Moracizine (ethmozine) is a phenothiazine derivative with demonstrated antiarrhythmic activity. To characterize the pharmacokinetics and material balance relationships in humans, we have given14C-moracizine·HCl as a single oral dose of 500 mg (50 μCi) to six healthy men. Plasma, urine, and faecal samples were collected for 7 days after administration and the concentrations of total radioactivity and intact moracizine were determined by liquid scintillation counting and HPLC, respectively.
Urine and faecal recovery accounted for 95% of the administered radioactivity. Most of this radioactivity was found in the faeces (59%). Only 0.05% of the dose was recovered from urine as intact moracizine.
The Cmax and AUC for moracizine equivalents of total radioactivity were 4- and 18-fold higher, respectively, than the corresponding values for intact moracizine. Additionally, both the disappearance of total radioactivity from plasma and its excretion rate into urine were slower in comparison to intact drug. Terminal t1/2 values calculated from plasma concentration-time data were 85.2 and 3.5 h for total radioactivity and intact moracizine, respectively. However, based on urinary excretion rates, the t1/2 for total radioactivity was shorter (29.3 h) while the t1/2 for intact drug was comparable (2.7 h) to the results obtained from the plasma data. The oral plasma clearance of moracizine was relatively large (2.2l·min−1), suggesting first-pass metabolism. The estimated oral systemic availability of moracizine was 34%.
Key wordsmoracizine·HCl antiarrhythmic ethmozine radiolabelled pharmacokinetics material balance healthy subjects
Unable to display preview. Download preview PDF.
- 1.Morganroth J, Orth DW, Michelson EL, Dunkman WB, Pearlman AS, Horowitz LN, Josephson ME, Kastor JA (1978) Comparative antiarrhythmic efficacy and tolerance of ethmozin and quinidine. Circulation 57/58 [Suppl. II]: 103Google Scholar
- 5.Pratt CM, Young JB, Francis MJ, Taylor AA, Norton HJ, English L, Mann DE, Kopelen H, Quinones MA, Roberts R (1984) Comparative effect of disopyramide and ethmozine in suppressing complex ventricular arrhythmias by use of a double-blind, placebo-controlled, longitudinal crossover design. Circulation 69: 288–297PubMedGoogle Scholar
- 7.Piotrovskii VK, Romina NN, Merkulova IN, Kurbanov, RD, Metelitsa VI, Mazar NA (1983) Bioavailability of ethmozine with oral administration [English translation]. Khim Farm Zh 221: 912–916Google Scholar
- 10.Vikhlyaev YI, Zherdev VP, Gritsenko AN, Ermakova ZI (1977) Features of ethmozine metabolism [English translation]. Farmakol Toksikol 40: 19–22Google Scholar
- 12.Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Marcel Dekker, New YorkGoogle Scholar
- 13.Lam FC, Hung CT, Perrier DG (1985) Estimation of variance for harmonic mean half-lives. J Pharm Sci 72: 229–231Google Scholar
- 16.Dubois D, Dubois EF (1916) A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 17: 863–871Google Scholar
- 17.Rowland M, Tozer TN (1980) Clinical pharmacokinetics — concepts and applications, Lea and Febiger, PhiladelphiaGoogle Scholar
- 18.Hollister LE (1983) Antipsychotic drugs. In: Clinical pharmacology of psychotherapeutic drugs, 2nd edn. Churchill Livingstone, New YorkGoogle Scholar